Abstract
The aim of this study was to investigate the effect of desensitization (DS) with intravenous immunoglobulin and rituximab (IVIG-RIT-IVIG) on the antibody profile in highly sensitized kidney transplant candidates (TC). In 31 kidney transplant candidates (calculated percent reactive antibodies [cPRA], 34% to 99%), DS included intravenous immunoglobulin on days 0 and 30 and a single dose of rituximab on day 15. Anti-HLA antibodies were analyzed before and after immunomodulation using the Luminex single antigen solid phase analysis. Reduction of cPRA from −25% to −50% was noted for anti-class I (5 patients, within 20 to 60 d) and anti-class II (3 patients, within 10 to 20 d) antibodies. After initial reduction of cPRA, it increased within 120 days. In 24 patients, decrease in mean fluorescence intensity (MFI) of antibodies by more than 50% was noted at follow-up, but there was no reduction of cPRA. Rebound occurred in 65% patients for anti-class I antibodies at 350 days and anti-class II antibodies at 101 to 200 days. Probability of rebound effect was higher in patients with MFI > 10700 before DS, anti-class II antibodies, and history of previous transplant. The desensitization protocol consisting of IVIG-RIT-IVIG had selective efficacy in highly sensitized kidney TC because of the short period with antibody reduction and high frequency of rebound effect.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
